PMID- 29759835 OWN - NLM STAT- MEDLINE DCOM- 20190723 LR - 20190723 IS - 2405-5018 (Electronic) IS - 2405-500X (Linking) VI - 3 IP - 13 DP - 2017 Dec 26 TI - Hemodynamic Support in Ventricular Tachycardia Ablation: An International VT Ablation Center Collaborative Group Study. PG - 1534-1543 LID - S2405-500X(17)30539-X [pii] LID - 10.1016/j.jacep.2017.07.005 [doi] AB - OBJECTIVES: This study sought to evaluate the clinical outcomes of patients receiving hemodynamic support (HS) during ventricular tacchycardia (VT) ablation. BACKGROUND: There are limited real-world data evaluating its effect of HS in ablation outcomes. METHODS: An analysis of 1,655 patients from the International VT Ablation Center Collaborative group was performed. A total of 105 patients received HS with percutaneous ventricular assist device. RESULTS: Patients in the HS group had lower left ventricular ejection fraction (LVEF), higher New York Heart Association (NYHA) functional class, and more implantable cardioverter-defibrillator (ICD) shocks, VT storm, and antiarrhythmic drug use (all p < 0.05). The HS group also required significantly longer fluoroscopy, procedure, and total lesion time. Acute procedural success (71.8% vs. 73.7%; p = 0.04) was significantly lower and complications (12.5% vs. 6.5%; p = 0.03) and 1-year mortality (34.7% vs. 9.3%; p < 0.001) were significantly higher in the HS group. Multivariate Cox regression analysis demonstrated HS as an independent predictor of mortality (hazard ratio: 5.01; 95% confidence interval: 3.44 to 7.20; p < 0.001). There was no significant difference in VT recurrence between groups. In a subgroup analysis including LVEF